Machine learning has long been used at UMC. In fact, our vigiGroup method stems from neural networks pioneered by one of this year’s Nobel laureates in Physics.

In focus / 05 December 2024

Since its introduction 20 years ago, UMC’s adverse event reporting system has become the world’s most widely used safety surveillance toolkit for medicines and vaccines.

WHO programme / 25 November 2024

Compared to the general population, older adults are more at risk of experiencing adverse drug reactions. Why is this the case, and what does this mean for pharmacovigilance?

In focus / 29 October 2024

AI holds potential to transform pharmacovigilance. But navigating the risks requires critical assessment. This article explores AI's evolving role in medicines safety.

Research / 22 October 2024